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AbstrACt
Objectives For 300 paediatric trials, we evaluated the 
reporting of: a data monitoring committee (DMC); interim 
analyses, stopping rules and early stopping; and adverse 
events and harm-related endpoints.
Methods For this cross-sectional evaluation, we 
randomly selected 300 paediatric trials published in 2012 
from the Cochrane Central Register of Controlled Trials. We 
collected data on the reporting of a DMC; interim analyses, 
stopping rules and early stopping; and adverse events 
and harm-related endpoints. We reported the findings 
descriptively and stratified by trial characteristics.
results Eighty-five (28%) of the trials investigated 
drugs, and 18% (n=55/300) reported a DMC. The reporting 
of a DMC was more common among multicentre than 
single centre trials (n=41/132, 31% vs n=14/139, 10%, 
p<0.001) and industry-sponsored trials compared with 
those sponsored by other sources (n=16/50, 32% vs 
n=39/250, 16%, p=0.009). Trials that reported a DMC 
enrolled more participants than those that did not (median 
[range]): 224 (10–60480) vs 91 (10–9528) (p<0.001). Only 
25% of these trials reported interim analyses, and 42% 
reported stopping rules. Less than half (n=143/300, 48%) 
of trials reported on adverse events, and 72% (n=215/300) 
reported on harm-related endpoints. Trials that reported a 
DMC compared with those that did not were more likely to 
report adverse events (n=43/55, 78% vs 100/245, 41%, 
p<0.001) and harm-related endpoints (n=52/55, 95% vs. 
163/245, 67%, p<0.001). Only 32% of drug trials reported 
a DMC; 18% and 19% did not report on adverse events or 
harm-related endpoints, respectively.
Conclusions The reporting of a DMC was infrequent, 
even among drug trials. Few trials reported stopping rules 
or interim analyses. Reporting of adverse events and 
harm-related endpoints was suboptimal.
IntrOduCtIOn
Data monitoring committees (DMCs) help 
to ensure ethical conduct and participant 
safety in trials via frequent risk–benefit 
appraisals to identify ‘definitive evidence 
of benefit, convincing evidence of harm, or 
sufficient evidence of no potential benefit’.1 
These periodic appraisals (ie, interim anal-
yses) are used to inform recommendations 
regarding trial modification, continuation 
or termination (ie, early stopping) based 
on pre-established stopping rules.2–4 In 
order to provide credible and unbiased 
monitoring of ongoing trials, members of 
the DMC must be independent of the trial 
sponsor and typically include a statistician 
and a clinical expert in the therapeutic area 
being investigated.5 In trials that investigate 
high-risk interventions and/or that recruit 
from vulnerable populations, the inclusion 
of bioethicists and patient or parent advo-
cates should also be considered.5 
Although safety and efficacy data should 
be monitored in all trials, formal establish-
ment of a DMC might not be needed in 
trials where the intervention(s) are known 
to cause minimal risk, or trials of behavioural 
What is already known on this topic?
 ► Data monitoring committees aim to safeguard par-
ticipants and ensure rigorous conduct in trials. They 
are recommended for trials that recruit from vulner-
able populations, including children.
 ► Reviews of trials published from 1996 to 2002 and 
2005 to 2007 showed that the reporting of data 
monitoring committees was infrequent in paediatric 
trials.
 ► Despite not always requiring an independent data 
monitoring committee, the monitoring of safety data 
is always warranted in paediatric trials.
What this study hopes to add?
 ► In a randomly selected sample of 300 paediatric 
trials published in 2012, 18% reported a data mon-
itoring committee.
 ► Fifty-two per cent of trials did not report any adverse 
events data.
 ► Only 32% of drug trials reported a data monitoring 
committee; 18% and 19% did not report on adverse 
events or harm-related endpoints, respectively.
 o
n
 20 June 2019 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2018-000426 on 20 March 2019. Downloaded from 
2 Gates A, et al. BMJ Paediatrics Open 2019;3:e000426. doi:10.1136/bmjpo-2018-000426
Open access
interventions or that analyse administrative data.6 For 
other trials, deciding whether a DMC is required should 
be based on the level of safety concern (eg, unknown 
risks or known risks), the practicality of having a DMC 
and whether having a DMC would help ensure the scien-
tific validity of the trial.6 DMCs are always required for 
trials that evaluate new drugs, biologicals or devices. In 
those that recruit from vulnerable populations, their 
establishment should be strongly considered.2 3
As children are typically considered to be vulnerable 
individuals, DMCs are frequently warranted in paediatric 
trials; however, earlier reviews showed that DMCs were 
seldom reported.7–9 Moreover, reviews of trials investi-
gating treatments for common paediatric conditions 
have found their reporting of harms to be suboptimal, 
limiting their utility for clinical decision making.10 11 In 
an evaluation of a random sample of 300 paediatric trials 
published in 2007, at which time only limited evidence-
based guidance was available for paediatric trials, just 
5% reported a DMC and 43% reported adverse events 
data.9 Since that time, Standards for Research in (StaR) 
Child Health published six evidence-based standards 
addressing priority issues regarding the conduct and 
reporting of paediatric trials, including guidance on the 
establishment of DMCs.12–18
As the use of DMCs in trials continues to evolve, and 
in light of the newly published guidance for the conduct 
and reporting of paediatric trials, we evaluated a sample 
of paediatric trials published in 2012 to determine the 
reporting of three distinct but related issues: (A) a DMC, 
its members and their responsibilities; (B) interim anal-
yses, stopping rules and early stopping; and (C) adverse 
events and harm-related endpoints.
MethOds
Context
Our methods have been detailed in previous reports.19 20 
A brief description follows.
sample selection
In November 2013, we searched the Cochrane Central 
Register of Controlled Trials (CENTRAL) for trials 
published in 2012.19 20 CENTRAL is a comprehensive 
database of reports of randomised and quasirandomised 
trials, taken mainly from MEDLINE and Embase.21 As 
this project was part of an ongoing surveillance initia-
tive,19 the 2012 publication date was chosen because it 
was 5 years following an earlier evaluation of a random 
sample of 300 paediatric trials undertaken in 2007.9 The 
date also coincided with the publication of the StaR Child 
Health Standards, allowing for the establishment of base-
line data for the reporting of priority items outlined 
within each.
We randomly ordered the 2296 unique records 
retrieved by the search using a computer-generated list 
in Excel (V.2016, Microsoft Corporation, Redmond, 
Washington, USA). Next, a single researcher screened 
the records by title and abstract and selected the first 
300 (13%) trials that reported on outcomes for partici-
pants aged 0–18 years or that recruited both children and 
adults with an upper age limit of 21 years. The sample 
size was selected based on our previous evaluation of 
trials published in 2007.9 We did not restrict the sample 
by language, condition, intervention or outcome type.
data extraction
We extracted data from each trial using a standard form 
in Research Electronic Data Capture22 pertaining to 
the reporting of: the presence of a DMC (yes or no), its 
members (defined by their professional role, eg, statisti-
cian and healthcare provider) and their responsibilities 
(eg, adjustments to enrolment and reviewing safety data); 
interim analyses (yes or no), stopping rules (yes or no) and 
early stopping (yes or no, and reasons); and the monitoring 
for and occurrence of adverse events (yes or no, and type) 
and harm-related endpoints (yes or no, and type).
As part of the larger study, we collected data on charac-
teristics of the publication, trial design, intervention, trial 
conduct, trial sample, consent and recruitment, outcomes, 
conclusions, trial registration and risk of bias.19. 20 Our data 
extraction guide was modelled after that used in the 2007 
study,9 with new items added following consultation with 
clinical and methodological experts. The complete data 
extraction guide is available in a previous report,19 whereas 
that for the variables presented in this study is in online 
supplementary appendix 1. We classified the primary diag-
nostic category for each trial following the WHO’s Inter-
national Statistical Classification of Diseases and Related 
Health Problems 10th Revision.23 Table 1 shows our classi-
fication scheme for other relevant trial characteristics. Data 
related to consent and recruitment, study design, trial regis-
tration and risk of bias have been reported elsewhere.19 20
We used trial registers, published protocols and/or 
companion articles to complement data extraction when 
available. When a registration record was not cited in the 
publication, we searched the International Clinical Trials 
Registry Platform (http:// apps. who. int/ trialsearch/), 
ISRCTN Registry (http://www. isrctn. com/) and Google 
(http://www. google. ca/). We located registration 
records for 46% (n=138/300) of the trials.19 We used 
protocols and companion articles only when they were 
cited in the published reports. All data were extracted 
from the published trials by one researcher and verified 
by another (AG or MPD) to identify and correct errors 
or omissions.
Analyses
We analysed the data descriptively in SPSS Statistics (V.25, 
IBM Corporation, Armonk, New York, USA). We investi-
gated differences in reporting of DMCs, adverse events 
and harm-related endpoints by trial characteristics using 
the Fisher’s exact test and by sample size using the Mann-
Whitney test in StatXact (V.10.0, Cytel, Cambridge, Mary-
land, USA).
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Patient and public involvement
Patients and the public were not directly involved in any 
aspect of this research.
results
trial characteristics
The characteristics of the 300 trials have been reported19 
and are provided for context. Most (n=242/300, 81%) trials 
used a parallel design and were efficacy or superiority trials 
(n=279/300, 93%). Thirty-three (11%) were described as 
pilot or exploratory. The most common funding source was 
government funding (n=135/300, 45%), followed by private 
(n=81/300, 27%), academic (n=71/300, 24%), pharma-
ceutical (n=41/300, 14%) and industry funding (n=9/300, 
3%). The most common treatments investigated included 
drugs (n=85/300, 28%), communication, organisational or 
educational programmes (n=52/300, 17%), rehabilitation 
or psychosocial interventions (n=30/300, 10%) and medical 
devices (n=29/300, 10%). Nearly half (n=140/300, 47%) 
of the trials were undertaken at a single centre. The most 
common diagnostic categories included mental and behav-
ioural disorders (n=50/300, 17%), infectious and parasitic 
diseases (n=39/300, 13%), conditions of the respiratory 
system (n=30/300, 10%) and conditions originating during 
the perinatal period (n=28/300, 9%). The trials reported 
data for the following categories of primary outcomes: 
behavioural (n=46/300, 15%); biomarker (n=55/300, 
18%); pain (n=14/300, 5%); physiological (n=130/300, 
43%); psychological (n=28/300, 9%); techniques/training 
(n=13/300, 4%); and quality of life (n=5/300, 2%). Nine 
(3%) trials investigated primary outcomes that did not fit 
into any of these categories, for example, knowledge and 
healthcare costs.
data monitoring committees
About one-fifth (n=55/300, 18%) of trials reported a DMC 
(table 2). Among these, just 20% (n=11/55) reported on 
its composition. Membership most commonly included 
physicians (n=9/11, 82%) and statisticians (n=6/11, 
55%). No trial (n=0/11) reported the membership of a 
patient or consumer or community advocate. Sixty percent 
(n=33/55) of trials that reported a DMC also reported the 
responsibilities to which it was assigned. Among these, the 
most common were reviewing safety data (n=26/33, 79%), 
adjusting enrolment (n=7/33, 21%), and making recom-
mendations regarding trial termination (n=6/33, 18%) and 
trial conduct (n=6/33, 18%).
Reporting of a DMC was more common among multi-
centre than single centre trials (n=41/132, 31% vs 
n=14/139, 10%; p<0.001) (table 3). Trials that reported 
a DMC randomised larger numbers of participants than 
those that did not (median [range]: 224 (10–60480) vs 
91 (10–9528); p<0.001). Reporting a DMC was more 
common among trials that tested drugs (n=27/85, 32%), 
vaccines (n=5/14, 36%), alternative therapeutic inter-
ventions (n=4/14, 29%) and prevention or screening 
interventions (n=3/14, 21%) compared with those that 
tested communication, organisational or educational 
programmes (n=4/52, 8%), medical devices (n=2/29, 
7%) and rehabilitation or psychosocial interventions 
(n=1/30, 3%) (p=0.001). None (n=0/9) of the trials 
that tested surgeries or radiotherapy reported a DMC. 
Reporting of a DMC did not differ by primary outcome 
type (p=0.16). Trials with an industry or pharmaceu-
tical sponsor were more likely than those with other 
forms of sponsorship to report a DMC (n=16/50, 32% vs 
n=39/250, 16%) (p=0.009).
Table 1 Data extraction classification scheme
Classification Definition
Reasons for early stopping
  (A) Benefit Stopped because of benefit seen in the 
intervention group(s).
  (B) Harm Stopped because of harm seen in the 
intervention group(s).
  (C) Futility Stopped because continuing the trial would 
be futile relative to establishing a treatment 
benefit.
  (E) Funding Stopped because funding was for a specific 
timeframe or limited.
  (E) Recruitment Stopped because of lower than anticipated 
recruitment.
Reported adverse events
  (A) Severe harms Serious adverse events, for example, death, 
hospitalisation, life-threatening outcome, 
disability or permanent damage.
  (B) Any harm Described non-specifically as ‘side effects’ or 
‘any/total/overall adverse events’.
  (C) Organ system level 
harms
Described non-specifically as adverse 
events in the organ systems, for example, 
cardiovascular adverse events and 
gastrointestinal adverse events.
  (D) Specific harms Described specifically, for example, nausea, 
headache and vomiting.
Reported harm-related endpoints
  (A) Discontinuations due to 
adverse events
Participants discontinued the trial due to 
adverse events.
  (B) Unexplained 
withdrawals
Participants withdrew from the trial, but the 
reason is not reported or reportedly unknown 
(could be due to adverse events or lack of 
efficacy).
  (C) Mortality Death from any cause (could be disease 
progression, adverse events or lack of 
efficacy).
Primary outcome category
  (A) Behavioural For example, attitudes and eating behaviours.
  (B) Biomarker For example, blood glucose and urine 
cultures.
  (C) Pain For example, pain relief and pain prevention.
  (D) Physiological For example, disease progression and 
mortality.
  (E) Psychological For example, depression assessment 
scores and neuropsychological test.
  (F) Techniques/training For example, method of intubation and 
effectiveness of a focus group.
  (G) Quality of life For example, Short Form Health Survey (SF-
36), patient satisfaction.
  (H) Other Any outcome that does not fit in another 
category.
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Interim analyses, stopping rules and early stopping
Few trials that reported a DMC reported on any interim 
analyses (n=14/55, 25%) (table 2). Only 22% (n=12/355) 
of the trials reported stopping rules. Thirteen trials (4%) 
reported early stopping; reasons included inadequate 
recruitment (n=5/13, 38%), futility (n=5/13, 38%), 
benefit of the treatment (n=2/13, 15%) and funding 
limitations (n=1/13, 8%). No trial reported early stop-
ping due to harms. Less than one-third (n=4/13, 31%) of 
trials that reported early stopping also reported stopping 
rules.
Adverse events and harm-related endpoints
Less than half (n=134/300, 45%) of the trials reported 
a plan to collect data on adverse events in the methods 
section of the publication (table 4). About one-third 
(n=109/300, 36%) of trials specified the method by 
which they planned to collect adverse events data.
More than half (n=157/300, 52%) of the trials did not 
report any data related to adverse events. This included 
11% (n=15/134) of the trials that reported a plan to 
collect and 12% (n=13/109) of the trials that specified 
a method for collecting adverse events data. Among 
the 48% (n=143/300) of trials that reported data on 
adverse events, 36% (n=52/143) reported severe harms, 
11% (n=16/143) reported any harm (not individually 
described), 9% (n=13/143) reported organ system level 
harms and 74% (n=106/143) reported specific harms. 
Twenty-two trials (n=22/143, 15%) reported that no 
adverse events occurred. When adverse events data were 
reported, most trials (n=119/143, 83%) reported these 
by group (ie, intervention vs control, as opposed to 
aggregated data).
Seventy-two per cent (n=215/300) of trials reported 
information on harm-related endpoints. Among these, 
25% (n=54/215) reported discontinuations due to 
adverse events and 22% reported deaths during the trial 
(n=47/215). Fifty-three per cent (n=114/215) of these 
trials reported withdrawals for which the reason was 
either unknown or not disclosed by the authors. About 
one-quarter (n=57/215, 27%) of these trials reported 
that there were no withdrawals or discontinuations due 
to adverse events.
Trials that reported the presence of a DMC were more 
likely to report data on adverse events (n=43/55, 78% vs 
n=100/245, 41%; p<0.001) and harm-related endpoints 
(n=52/55, 95% vs n=163/245, 67%; p<0.001) (table 5). 
Adverse events data were most commonly reported 
among trials that examined vaccines (n=12/14, 86%) 
and drugs (n=70/85, 82%) and infrequently reported 
among trials that examined communication, organisa-
tional or educational programmes (n=4/52, 8%) and 
rehabilitation or psychosocial interventions (n=4/30, 
13%) (p<0.001). Harm-related endpoints data were most 
commonly reported among trials that examined vaccines 
(n=14/14, 100%), drugs (n=69/85, 81%), medical 
devices (n=20/29, 69%), surgery or radiotherapy (n=6/9, 
67%) and rehabilitation or psychosocial interventions 
(n=20/30, 67%). They were less commonly reported 
among trials that examined prevention or screening 
programmes (n=8/14, 57%), communication, organi-
sational or educational programmes (n=28/52, 54%) 
Table 2 Reporting of DMCs, interim analyses, stopping 
rules and early stopping
Trial characteristic N total N (%)
DMCs
  Reported 300 55 (18)
  Not reported 245 (82)
DMC members*
  Physician 55 9 (16)
  Statistician 6 (11)
  Clinical trial methodologist 1 (2)
  Clinical pharmacologist 3 (5)
  Bioethicist 1 (2)
  Other 3 (5)
  Not specified 44 (80)
DMC responsibilities†
  Adjustment to enrolment 55 7 (13)
  Make recommendations regarding 
termination
6 (11)
  Review or approve the protocol 3 (6)
  Review or make recommendations 
about trial conduct
6 (11)
  Release interim data 1 (2)
  Review or approve manuscripts or 
reports
2 (4)
  Review safety data 26 (47)
  Other‡ 4 (7)
  Not reported 22 (40)
Reported on interim analyses
  Yes 55 14 (25)
  No 41 (75)
Reported on stopping rules
  Yes 55 12 (22)
  No 43 (78)
Reported that the trial stopped early
  Yes 300 13 (4)
  For benefit 2/13 (15)
  For harm 0/13 (0)
  For futility 5/13 (38)
  Due to funding limitation 1/13 (8)
  Due to inadequate recruitment 5/13 (38)
  No 287 (96)
*Nine of the 11 trials (82%) that reported on membership in the 
DMCs reported more than one type of member.
†13 of the 33 trials (39%) that reported on the DMC’s 
responsibilities reported more than one responsibility.
‡Included changes to the statistical analyses and maintaining the 
randomisation sequence.
DMCs, data monitoring committee.
 o
n
 20 June 2019 by guest. Protected by copyright.
http://bmjpaedsopen.bmj.com/
bmjpo: first published as 10.1136/bmjpo-2018-000426 on 20 March 2019. Downloaded from 
5Gates A, et al. BMJ Paediatrics Open 2019;3:e000426. doi:10.1136/bmjpo-2018-000426
Open access
and alternative therapeutic interventions (n=8/14, 57%) 
(p=0.002).
dIsCussIOn
Of the trials that we evaluated, 18% reported a DMC. 
This compares to 14% for paediatric trials published in 
2005–20077 and 2% for those published in 1996–2002,8 
according to earlier reviews. As children are a vulner-
able population, some would suggest that all paediatric 
trials should be overseen by a DMC.10 Nevertheless, the 
decision whether to establish a DMC in a paediatric trial 
is dependent on various considerations (clinical, method-
ological and otherwise),15 most of which are not available 
in published reports. It is thus likely that a number of the 
trials in our sample did not require a DMC; however, it is 
encouraging that their establishment was more frequent 
among those that investigated drugs, vaccines and alter-
native therapeutic interventions compared with those 
that investigated behavioural, rehabilitation or psychoso-
cial programmes. Notably, the reporting of a DMC was 
Table 3 Reported presence of a data monitoring committee stratified by trial characteristics
Trial characteristic N
Data monitoring committee, N (%)
P value
Reported
55 (18)
Not reported
245 (82)
Number of centres
  Single centre 139 14 (10) 125 (90) <0.001
  Multicentre 132 41 (31) 91 (69)
  Unclear 29 0 (0) 29 (100)
Number of nations
  Single nation 281 48 (17) 233 (83) 0.06
  Multinational 19 7 (37) 12 (63)
Sample size
  N randomised, median (range) 300 224 (10–60480) 91 (10–9528) <0.001
Nature of the intervention
  Drug 85 27 (32) 58 (68) 0.001
  Vaccine 14 5 (36) 9 (64)
  Rehabilitation or psychosocial 30 1 (3) 29 (97)
  Prevention or screening 14 3 (21) 11 (79)
  Surgery or radiotherapy 9 0 (0) 9 (100)
  Communication, organisational or 
educational
52 4 (8) 48 (92)
  Alternative therapeutic 14 4 (29) 10 (71)
  Device 29 2 (7) 27 (93)
  Other* 53 9 (17) 44 (83)
Primary outcome type
  Behavioural 46 4 (9) 42 (91) 0.16
  Biomarker 55 12 (22) 43 (78)
  Pain 14 3 (21) 11 (79)
  Physiological 130 31 (24) 99 (76)
  Psychological 28 2 (7) 26 (93)
  Techniques/training 13 1 (8) 12 (92)
  Quality of life 5 0 (0) 5 (100)
  Other 9 2 (22) 7 (78)
Industry or pharmaceutical funding
  Yes 50 16 (32) 34 (68) 0.009
  No 250 39 (16) 211 (84)
*Included therapeutic nutritional interventions (eg, supplements, infant formula and probiotics), sensorimotor interventions, physical activity 
interventions and financial interventions.
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infrequent among trials that investigated surgeries, radi-
otherapy or devices where, especially in paediatric popu-
lations, their establishment may be warranted.
Less than half of the trials in our sample reported data 
on harms, a finding that compares to previous reviews 
of trials in specific topic areas. For example, Hum et al10 
noted suboptimal reporting of harms in paediatric trials 
of antibiotics for acute otitis media. Moreover, Leung 
et al11 identified several methodological issues related 
to the identification and reporting of adverse events in 
paediatric studies of asthma medications. Incomplete 
reports of trials limit healthcare providers’ ability to make 
decisions based on consideration of both the benefits 
and risks of available treatments.24 25 We found that the 
reporting of adverse events was infrequent among trials 
that may be presumed to pose lesser risk (eg, commu-
nication, organisational or educational programmes and 
rehabilitation or psychosocial interventions); however, 
even in low-risk populations and putatively low-risk inter-
ventions, ‘the balance of harms and benefits may easily 
lean toward harm’.26
Of the 143 trials that did report data on harms, 36% 
reported severe harms. Moreover, of the 215 trials that 
reported on harm-related endpoints, 54% reported 
discontinuations due to adverse events. By contrast, 
none of the trials in our sample reported early stopping 
due to harms. Ethically, trials must stop early when the 
findings of interim analyses show that exposing partici-
pants to additional potential risk by participating in the 
trial is not justified.27 Thus, the occurrence of harms 
is not an indication to stop a trial, unless the accruing 
harms data show unreasonable risk from participation 
compared with the anticipated benefits.27 An important 
issue is that more than half of the trials we analysed did 
not report any data related to harms. Because it is not 
possible to uphold ethical standards for trial conduct if 
harms data are not collected and monitored, this likely 
reflects a reporting issue. Similarly, a review of adverse 
event reporting in published and unpublished reports of 
studies of healthcare interventions found strong evidence 
that much of the information on adverse events remains 
unpublished.28
Implications for research and practice
Many trialists cite inadequate knowledge and paediat-
ric-specific methodological training as serious barriers 
to the rigorous conduct and reporting of trials involving 
children.29–31 Encouragement of prospective protocol 
publication, learning opportunities for trialists and 
trainees and the vigilant review of the reporting of 
DMCs and adverse events data by reviewers and editors 
of academic journals may contribute to improvements in 
conduct and reporting. As it was not feasible in this study 
to appraise the independency of members of the DMCs 
from trial sponsors or investigators (which is necessary 
to ensure unbiased monitoring), we cannot draw any 
conclusions regarding DMC conduct. Future studies may 
consider addressing this knowledge gap.
strengths and limitations
We evaluated trials published in 2012, providing a base-
line for ongoing evaluation of safety monitoring proce-
dures in paediatric trials; however, the findings may not 
be reflective of present-day conduct and reporting. More-
over, because we investigated a random sample of trials, 
not all of the trials would have required a DMC. Never-
theless, ongoing evaluation of the state of the research 
is needed to evaluate changes over time and identify the 
areas in most need of attention. The random nature of 
our sample facilitated comparisons with previous studies, 
Table 4 Reporting of adverse events and harm-related 
endpoints
Trial characteristic N total N (%)
Plans to collect data on adverse events or side effects (in 
methods)
  Reported 300 134 (45)
  Not reported 166 (55)
Method for collecting adverse events data
  Specified 300 109 (36)
  Not specified 191 (64)
Adverse events*
  Reported data on harms 300 143 (48)
  Reported severe harms 52/143 (36)
  Reported any harm (not 
individually described)
16/143 (11)
  Reported organ-system 
level harms
13/143 (9)
  Reported specific harms 106/143 (74)
  Reported that no harms 
occurred
22/143 (15)
  Did not report data on 
harms
157 (52)
Harm-related endpoints†
  Reported data on harm-
related endpoints
300 215 (72)
  Reported discontinuations 
due to adverse events
54/215 (25)
  Reported unexplained 
withdrawals
114/215 (53)
  Reported mortality 47/215 (22)
  Reported no 
discontinuations due to 
adverse events
57/215 (27)
  Did not report data on 
harm-related endpoints
85 (28)
*52 of the 121 trials (43%) that reported harms reported more than 
one type of harm.
†51 of the 158 trials (32%) that reported the occurrence of harm-
related endpoints reported more than one type of harm-related 
endpoint.
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including a similar descriptive analysis of paediatric trials 
published in 2007.9
Limitations of our findings stem from our reliance 
on the data provided in published reports. Because the 
reporting of serious adverse events is a regulatory require-
ment for many clinical trials, it is likely that our findings 
represent reporting shortcomings. Moreover, we exam-
ined only whether adverse events were reported, not 
whether the adverse events investigated were appropriate 
or adequate. Because we sampled trials published in 2012 
covering various conditions, interventions and outcomes, 
our findings may not be generalisable to trials of specific 
conditions or interventions, measuring specific outcomes 
or published in other years.
COnClusIOns
The reporting of a DMC was infrequent within our 
sample. It was more common among trials that investi-
gated drugs, vaccines and alternative therapies, multi-
centre trials, industry-sponsored trials and those that 
enrolled larger samples. Adverse events data were 
reported in less than half of the trials, which has impor-
tant implications for the ability of paediatric trials to 
inform clinical decision making.24 25 None of the trials in 
our sample reported early stopping due to harms.
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Table 5 Reporting of adverse events and harm-related endpoints stratified by the nature of the intervention
Nature of the intervention N
Reported data on adverse 
events, N (%)
P value
Reported data on harm-
related endpoints, N (%)
P value
Yes
143 (48)
No
157 (52)
Yes
215 (72)
No
85 (28)
Data monitoring committee
  Reported 55 43 (78) 12 (22) <0.001 52 (95) 3 (6) <0.001
  Not reported 245 100 (41) 145 (59) 163 (67) 82 (34)
Nature of the intervention
  Drug 85 70 (82) 15 (18) <0.001 69 (81) 16 (19) 0.002
  Vaccine 14 12 (86) 2 (14) 14 (100) 0 (0)
  Rehabilitation or psychosocial 30 4 (13) 26 (87) 20 (67) 10 (33)
  Prevention or screening 14 5 (36) 9 (64) 8 (57) 6 (43)
  Surgery or radiotherapy 9 5 (56) 4 (44) 6 (67) 3 (33)
  Communication, 
organisational or educational
52 4 (8) 48 (92) 28 (54) 24 (46)
  Alternative therapeutic 14 9 (64) 5 (36) 8 (57) 6 (43)
  Device 29 16 (55) 13 (45) 20 (69) 9 (31)
  Other* 53 18 (34) 35 (66) 42 (79) 11 (21)
*Included therapeutic nutritional interventions (eg, supplements, infant formula and probiotics), sensorimotor interventions, physical activity 
interventions and financial interventions.
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